TORONTO, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Altus Group Limited (“Altus Group” or “the Company”) (TSX: AIF), a leading provider of asset and fund intelligence for commercial real estate (“CRE”), announced today its financial and operating results for the …
LOUISVILLE, Colo., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Solid Power, Inc. (Nasdaq: SLDP), a leading developer of solid-state battery technology, today announced its operational and financial results for the third quarter of 2024. Recent Business Highlights …
MARLBOROUGH, Mass. and YOKNEAM ILIT, Israel, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Lifeward Ltd. (Nasdaq: LFWD) (“Lifeward” or the “Company”), a global market leader delivering life-changing solutions in physical rehabilitation and recovery, announced the …
CEDARHURST, N.Y., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Postal Realty Trust, Inc. (NYSE: PSTL) (the “Company”), an internally managed real estate investment trust that owns and manages over 2,000 properties leased primarily to the United States Postal Service …
Reports Net Investment Income of $0.63 Per Share and Net Asset Value of $20.36 Per Share Recurring PIK Income as a Percentage of Total Investment Income Declines by Over 200 Basis Points Continued Share Repurchase Program: Total of 33,429 Shares for an …
SAN JOSE, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Nutanix, Inc. (NASDAQ: NTNX), a leader in hybrid multicloud computing, today announced that it will report its financial results for the first quarter of fiscal year 2025, which ended October 31, 2024, after U.S. …
Company to present trem-cel + Mylotarg clinical data update at American Society of Hematology (ASH) 2024 annual meeting Han Choi, M.D., LL.M, seasoned healthcare institutional investor, appointed as Chief Financial Officer CAMBRIDGE, Mass., Nov. 07, 2024 ( …
– Topline results from registration-directed trial of ziftomenib in R/R NPM1-mutant AML expected in early 2025; Phase 1 results published in The Lancet Oncology – – Data from 100 patients in Phase 1a dose-escalation study of ziftomenib combined with ven/ …
CAMBRIDGE, Mass., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) …
CHICAGO, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Sprout Social, Inc. (“Sprout Social”, the “Company”) (Nasdaq: SPT), an industry-leading provider of cloud-based social media management software, today announced financial results for its third quarter ended …
DENVER, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Medicine Man Technologies, Inc., operating as Schwazze, (OTC: SHWZ) (Cboe CA: SHWZ) ("Schwazze" or the "Company"), today announced preliminary financial and operational results for the third …
Ersodetug, a novel, fully human monoclonal antibody for the treatment of hyperinsulinism (HI), advancing in two late-stage, registrational clinical trials in two indications Phase 3 sunRIZE study on track; U.S. enrollment expected to commence in the first …
Acquired ImmPACT Bio and strengthened clinical pipeline with the addition of IMPT-314, a dual-targeting CD19/CD20 CAR T-cell product candidate with strong Phase 1 clinical data in patients with aggressive relapsed/refractory B-cell non-Hodgkin’s lymphoma …
SAN JOSE, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced that the …
- Published positive Phase 2 trial results of onvansertib in combination with FOLFIRI and bev in second-line KRAS mutant mCRC in the peer-reviewed Journal of Clinical Oncology - - Initial data readout from first-line RAS-mutated mCRC randomized CRDF-004 …
Earnings Release: Wednesday, November 13, 2024, After Market Closes Conference Call and Webcast: Thursday, November 14, 2024, at 9:00 A.M. Eastern Time MONACO, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Safe Bulkers, Inc. (the Company) (NYSE: SB), an international …
SEATTLE, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products …
Maintained Robust Gross Profit Margin of 45.4% Through Operational Efficiency and Strategic Growth in Key Markets Net Loss of $16.0 million, compared to $20.6 million in Q3 2023 Adjusted EBITDA of $10.3 million increased 6.5% year-over-year Continued …
SALT LAKE CITY, Nov. 07, 2024 (GLOBE NEWSWIRE) -- LifeVantage Corporation (Nasdaq: LFVN), a leading health and wellness company with products designed to activate optimal health processes at the cellular level, today announced that Steve Fife, President …
Positive Phase 1a interim data released for ABI-5366, a long-acting HSV helicase-primase inhibitor candidate for recurrent genital herpes, supporting potential for once-weekly and once-monthly oral dosing First participants dosed in Phase 1b trial …
